UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 3)¹

Blueprint Medicines Corporation (Name of Issuer)

Common Stock, \$0.001 par value (Title of Class of Securities)

09627Y109

(CUSIP Number)

December 31, 2016

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- o Rule 13d-1(b)
- x Rule 13d-1(c)
- o Rule 13d-1(d)

¹ The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, *see* the *Notes*).

1				
1	NAME OF REPORTING PERSON			
	Biotechnology Value Fund, L.P.			
2	CHECK THE APPF	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) x	
			(b) o	
3	SEC USE ONLY			
4	CITIZENSHIP OR	PLACE OF ORGANIZATION		
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES				
BENEFICIALLY		0 shares		
OWNED BY EACH	6	SHARED VOTING POWER		
REPORTING				
PERSON WITH		1,564,734		
	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		1,564,734		
9	AGGREGATE AM	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,564,734			
10	CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
		· · ·		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		-	
	4.8%			
12	TYPE OF REPORT	ING PERSON		
	PN			
<u></u>				

2	Biotechnology Value CHECK THE APPR	OPRIATE BOX IF A MEMBER OF A GROUP	(a) x
-			(b) o
3	SEC USE ONLY		
4	CITIZENSHIP OR P	LACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES BENEFICIALLY		0 shares	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING			
PERSON WITH		959,457	
	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		959,457	
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	959,457		
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
	3.0%		
12	TYPE OF REPORTIN	NG PERSON	
	PN		

1	MANE OF DEPOPT	NO DEDCOM		
	NAME OF REPORTING PERSON			
	Distachuslogy Value Trading Fund OS I D			
	Biotechnology Value Trading Fund OS LP			
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x			
3	SEC USE ONLY		(b) o	
3	SEC USE ONLY			
4	CITIZENSUID OD DI	ACE OF ORGANIZATION		
4	CITIZENSIIIF OK FI	LACE OF ORGANIZATION		
	Cayman Islands			
NUMBER OF	5	SOLE VOTING POWER		
SHARES	-			
BENEFICIALLY		0 shares		
OWNED BY EACH	6	SHARED VOTING POWER		
REPORTING				
PERSON WITH		238,070		
	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		238,070		
9	AGGREGALE AMO	JNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	238,070			
10				
10	CHECK DUA IF INI	AGOALOATE AMOUNT IN KOW (3) EAGLODES CENTAIN SHARES		
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
11				
	Less than 1%			
12	TYPE OF REPORTING PERSON			
	PN			

1					
1	NAME OF REPORTING PERSON				
2	BVF Partners OS Ltd.				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x (b) o				
3	SEC USE ONLY		(0) 0		
5	SEC USE UNLI				
4	CITIZENSHID OR DI	ACE OF ORGANIZATION			
4		LACE OF OKGANIZATION			
	Cayman Islands				
NUMBER OF	5	SOLE VOTING POWER			
SHARES					
BENEFICIALLY		0 shares			
OWNED BY EACH	6	SHARED VOTING POWER			
REPORTING					
PERSON WITH		238,070			
	7	SOLE DISPOSITIVE POWER			
	0	0 shares			
	8	SHARED DISPOSITIVE POWER			
		238,070			
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	238,070				
10	CHECK BOX IF THE	E AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES			
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)				
	Loss then 10/				
12	Less than 1% TYPE OF REPORTING PERSON				
12	I YPE OF REPORTIN	NG PEKJUIN			
	СО				
L	0				

L				
1	NAME OF REPORTING PERSON			
	BVF Partners L.P.			
2	CHECK THE APPR	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x		
			(b) o	
3	SEC USE ONLY			
4	CITIZENSHIP OR P	LACE OF ORGANIZATION		
	Delaware			
NUMBER OF	5	SOLE VOTING POWER		
SHARES	5	SOLE VOTING FOWER		
BENEFICIALLY		0 shares		
OWNED BY EACH	6	SHARED VOTING POWER		
REPORTING	, i i i i i i i i i i i i i i i i i i i			
PERSON WITH		3,255,280		
	7	SOLE DISPOSITIVE POWER		
		0 shares		
	8	SHARED DISPOSITIVE POWER		
		3,255,280		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	D 055 000			
10	3,255,280			
10	CHECK BOX IF TH	E AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		
11				
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)			
	10.1%			
12	TYPE OF REPORTI	NG PERSON		
12				
	PN, IA			
L	,			

1			
1	NAME OF REPORTING PERSON		
	BVF Inc.		
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) x		
			(b) o
3	SEC USE ONLY		
4	CITIZENCUID OD D		
4	CITIZENSHIP OR P	LACE OF ORGANIZATION	
	Delaware		
NUMBER OF	5	SOLE VOTING POWER	
SHARES	J	SOLE VOTING FOWER	
BENEFICIALLY		0 shares	
OWNED BY EACH	6	SHARED VOTING POWER	
REPORTING	0		
PERSON WITH		3,255,280	
	7	SOLE DISPOSITIVE POWER	
		0 shares	
	8	SHARED DISPOSITIVE POWER	
		3,255,280	
9	AGGREGATE AMO	UNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	3,255,280		
10	CHECK BOX IF TH	E AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)		
	10.1%		
12	TYPE OF REPORTI		
12	I I PE OF REPORT	ING PERSOIN	
	СО		
L	0		

[
1	NAME OF REPORTING PERSON					
	Mark N. Lampert	Mark N. Lampert				
2	CHECK THE APPRO	DPRIATE BOX IF A MEMBER OF A GROUP	(a) x			
			(b) o			
3	SEC USE ONLY					
4	CITIZENSHIP OR P	LACE OF ORGANIZATION				
	United States					
NUMBER OF	5	SOLE VOTING POWER				
SHARES						
BENEFICIALLY		0 shares				
OWNED BY EACH	6	SHARED VOTING POWER				
REPORTING						
PERSON WITH		3,255,280				
	7	SOLE DISPOSITIVE POWER				
		0 shares				
	8	SHARED DISPOSITIVE POWER				
		3,255,280				
9	AGGREGATE AMO	UNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	3,255,280					
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
	10.1%					
12	TYPE OF REPORTING PERSON					
	IN					
L						

CUSIP NO. 09627Y109

Item 1(a).	Name of Issuer:
	Blueprint Medicines Corporation, a Delaware corporation (the "Issuer").
Item 1(b).	Address of Issuer's Principal Executive Offices:
	38 Sidney Street, Suite 200 Cambridge, Massachusetts 02139
Item 2(a). Item 2(b). Item 2(c).	Name of Person Filing Address of Principal Business Office or, if None, Residence Citizenship
	Biotechnology Value Fund, L.P. ("BVF") 1 Sansome Street, 30 th Floor San Francisco, California 94104 Citizenship: Delaware
	Biotechnology Value Fund II, L.P. ("BVF2") 1 Sansome Street, 30 th Floor San Francisco, California 94104
	Citizenship: Delaware
	Biotechnology Value Trading Fund OS LP ("Trading Fund OS") PO Box 309 Ugland House
	Grand Cayman, KY1-1104 Cayman Islands Citizenship: Cayman Islands
	BVF Partners OS Ltd. ("Partners OS") PO Box 309 Ugland House
	Grand Cayman, KY1-1104 Cayman Islands
	Citizenship: Cayman Islands
	BVF Partners L.P. ("Partners") 1 Sansome Street, 30th Floor
	San Francisco, California 94104 Citizenship: Delaware
	BVF Inc.
	1 Sansome Street, 30 th Floor San Francisco, California 94104
	Citizenship: Delaware
	Mark N. Lampert ("Mr. Lampert") 1 Sansome Street, 30 th Floor San Francisco, California 94104 Citizenship: United States
	Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
	and concerned to the a reporting report and concerned, as the reporting reports

Item 2(d).	Title o	f Class of	f Securities:
	Comm	on Stock	s, \$0.001 par value (the "Common Stock")
Item 2(e).	CUSI	P Number	r.
	09627	Y109	
Item 3.	If This	Stateme	nt is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
	/x/	Not ap	plicable.
	(a)	//	Broker or dealer registered under Section 15 of the Exchange Act.
	(b)	//	Bank as defined in Section 3(a)(6) of the Exchange Act.
	(c)	//	Insurance company as defined in Section 3(a)(19) of the Exchange Act.
	(d)	//	Investment company registered under Section 8 of the Investment Company Act.
	(e)	//	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
	(f)	//	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
	(g)	//	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
	(h)	//	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
	(i)	//	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
	(j)	//	Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
	(k)	//	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
Item 4.	Ownership		
	(a) Amount beneficially owned:		nt beneficially owned:
	As of the close of hypiness on December 21, 2016 (i) DVE heneficially exmed 1 E64 724, charge of Common Steels (ii) D		

As of the close of business on December 31, 2016 (i) BVF beneficially owned 1,564,734 shares of Common Stock, (ii) BVF2 beneficially owned 959,457 shares of Common Stock, and (iii) Trading Fund OS beneficially owned 238,070 shares of Common Stock.

Partners OS as the general partner of Trading Fund OS may be deemed to beneficially own the 238,070 shares of Common Stock beneficially owned by Trading Fund OS.

Partners, as the general partner of BVF, BVF2, the investment manager of Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 3,255,280 shares of Common Stock beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and certain Partners managed accounts (the "Partners Managed Accounts"), including 493,019 shares of Common Stock held in the Partners Managed Accounts.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 3,255,280 shares of Common Stock beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 3,255,280 shares of Common Stock beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Partners OS disclaims beneficial ownership of the shares of Common Stock beneficially owned by Trading Fund OS. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Accounts, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

(b) Percent of class:

The following percentages are based on 32,307,556 shares of Common Stock outstanding, as disclosed in the Issuer's Prospectus filed on Form 424B5 with the Securities and Exchange Commission on December 8, 2016.

As of the close of business on December 31, 2016 (i) BVF beneficially owned approximately 4.8% of the outstanding shares of Common Stock, (ii) BVF2 beneficially owned approximately 3.0% of the outstanding shares of Common Stock, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding shares of Common Stock (iv) Partners OS may be deemed to beneficially own less than 1% of the outstanding shares of Common Stock, and (v) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 10.1% of the outstanding shares of Common Stock (approximately 1.5% of which is held in the Partners Managed Accounts).

- (c) Number of shares as to which such person has:
- (i) Sole power to vote or to direct the vote

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of

See Cover Pages Items 5-9.



CUSIP NO. 09627Y109

Item 5.	Ownership of Five Percent or Less of a Class.		
	Not Applicable.		
Item 6.	Ownership of More than Five Percent on Behalf of Another Person.		
	Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the shares of Common Stock beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Managed Accounts.		
Item 7.	Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.		
	Not Applicable.		
Item 8.	Identification and Classification of Members of the Group.		
	See Exhibit 99.1 to Amendment No. 1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on February 16, 2016.		
Item 9.	Notice of Dissolution of Group.		
	Not Applicable.		
Item 10.	Certifications.		
By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.			

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2017

BIOTECHNOLOGY VALUE FUND, L.P.

- By: BVF Partners L.P., its general partner
- By: BVF Inc., its general partner

By: /s/ Mark N. Lampert Mark N. Lampert President BVF INC.

By: /s/ Mark N. Lampert

Mark N. Lampert President

/s/ Mark N. Lampert MARK N. LAMPERT

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF Partners L.P., its general partner

- By: BVF Inc., its general partner
- By: /s/ Mark N. Lampert

Mark N. Lampert President

BVF PARTNERS L.P.

- By: BVF Inc., its general partner
- By: /s/ Mark N. Lampert Mark N. Lampert President

BVF PARTNERS OS LTD.

- By: BVF Partners L.P., its sole member
- By: BVF Inc., its general partner
- By: /s/ Mark N. Lampert Mark N. Lampert President

BIOTECHNOLOGY VALUE TRADING FUND OS LP

- By: BVF Partners L.P., its investment manager
- By: BVF Inc., its general partner
- By: /s/ Mark N. Lampert

Mark N. Lampert President

